REDWOOD CITY, Calif., Aug. 26, 2014 /PRNewswire/ -- Guardant Health, a healthcare company focused on the development and commercialization of oncology diagnostic products, has been recognized today by the World Economic Forum as a 2015 Technology Pioneer. As an innovator in non-invasive, tumor profiling, Guardant Health is one of 24 companies across a wide variety of industries and regions to receive this prestigious accolade.
Guardant360®, Guardant Health's first commercially available product, is a first-in-kind blood test that comprehensively sequences a patient's cancer in real-time to aid oncologists in making more informed, personalized treatment decisions without the cost, time, and risk of a traditional tissue biopsy. Guardant360 is built on Digital SequencingTM technology, a proprietary method of capturing and genomically profiling trace fragments of tumor DNA that are shed into the blood stream ("cell-free DNA"), while also providing sequencing information at the single-molecule level. A patient's cancer genomics continues to evolve and change over time due to treatment pressure, which can cause therapy failure. For the first time, oncologists now have a way to easily track tumor changes with a simple blood test.
In just two years, Guardant Health has taken a promising idea through clinical validation and to commercial launch. Since launch, Guardant360 has demonstrated strong clinical utility as 75% of the genomic alterations identified in the patient specimens are actionable.
"We are honored to be recognized by the World Economic Forum and humbled to be among the esteemed past and present award winners," said Helmy Eltoukhy, Ph.D., Co-founder and Chief Executive Officer of Guardant Health. "Our mission remains the same: to turn cancer into a manageable disease. We stay committed to ensuring positive impact for patients and helping to reduce both the financial and physical burden of cancer."
About World Economic Forum The World Economic Forum is an independent international organization committed to improving the state of the world by engaging business, political, academic and other leaders of society to shape global, regional and industry agendas.
Incorporated as a not-for-profit foundation in 1971 and headquartered in Geneva, Switzerland, the Forum is tied to no political, partisan or national interests (www.weforum.org).
About Guardant Health Guardant Health is focused on developing breakthrough diagnostic technologies that possess the ability to transform cancer from a terminal illness to a manageable disease. Guardant was founded in 2012 by a team of entrepreneurs with high-ranking expertise in next-generation sequencing, single-cell genomics and cancer diagnostics. Guardant Health is committed to contributing a positive significant impact on patient health through cutting-edge technology that addresses long-standing unmet needs in oncology. (www.guardanthealth.com)